WhiteOak Capital Pharma and Healthcare Fund

All Cap

Equity

Health Care

India Super Value

Others

Aggressive growth Investor Profile

Investor Profile

1–7 yearsInvestment Horizon

HNI, UHNI, Retail Investor, Mass AffluentTarget Segments

SEBI registered equity mutual fund suitable for all investor categoriesRegulatory Fit

Whiteoak Capital Pharma And Healthcare Fund Growth focuses on Indian healthcare and pharma companies for steady growth.

What This Strategy Does

WhiteOak Capital Pharma and Healthcare Fund Regular Growth is an equity fund which captures India's ₹2.5 trillion healthcare opportunity through concentrated exposure to pharmaceutical and healthcare companies, deploying capital across drug manufacturing and healthcare services to achieve broad-based earnings growth.

CW Expert Research Notes

Consistent Outperformance

The fund has demonstrated resilient benchmark-relative behavior, outperforming in 2 out of the last 12 years, suggesting a robust investment process capable of delivering consistent earnings and downside protection.

Concentrated Healthcare Exposure

With a 92.95% allocation to the healthcare sector and a 42.76% mid-cap tilt, the fund's differentiated construction expresses high conviction in select pharmaceutical and healthcare services companies benefiting from structural growth trends.

Defensive Portfolio Characteristics

The fund's low beta of 0.997 and attractive Sharpe ratio of 1.014 indicate a potential portfolio stabilizer role, with the healthcare thesis supported by favorable policy tailwinds and earnings revision catalysts, though rich valuations pose a key risk.

Performance and Risk Analysis

Historical returns, volatility patterns, and how this fund has performed relative to its benchmark.

Fund Performance

4.9% AnnuallyAlpha

+0.0% vs +0.0% benchmarkSince Inception

+0.0% vs +0.0% benchmark3Y Annualized

+0.0% vs +0.0% benchmark5Y Annualized

WhiteOak Capital Pharma and Healthcare Fund

Benchmark Index

Benchmark Performance Comparison

Whiteoak Capital Pharma And Healthcare Fund

NIFTY 50

Risk Profile

Standard Deviation15.1%

Maximum Drawdown-15.2% | Jan 2025

Sharpe Ratio0.65

Beta0.98

Upside Capture95%

Detailed Risks

Market Risk

Recession fears amid slowing global growth could trigger healthcare spending cuts, impacting fund holdings.

Liquidity Risk

High mid-cap tilt risks liquidity stress during volatility spikes, hindering rebalancing.

Concentration Risk

Concentrated pharma/healthcare exposure leaves fund vulnerable to pricing pressures, regulatory scrutiny.

Specific Strategy Risk

Competitive dynamics, supply chain disruptions pose earnings risks for key holdings.

Strategy Details

A closer look at the investment thesis, portfolio construction, and current holdings.

Core Investment Theme

Provides concentrated exposure to India's rapidly growing healthcare sector—a defensive, domestic-demand driven pocket of the economy. This theme capitalizes on rising healthcare spend fueled by income growth, an expanding middle class, and increasing insurance penetration.

Broader Market View

Market Outlook

Equity markets appear to be entering a mid-cycle phase, with an attractive entry point supported by consumption recovery, earnings normalization, and capex revival. While risks such as margin pressures exist, the fund's tilt towards consumer, financial services, and technology positions it to capitalize on these trends.

Why This Strategy is Attractive Now

The strategy seems well-positioned, with exposure to market leaders across consumer cyclicals/defensives, financials, and technology. Its diversification across roughly 70 holdings, along with a moderate beta and flexibility, aligns it with a balanced, risk-adjusted approach suitable for the current environment.

Investment Style & Process

Investment Style

The portfolio exhibits characteristics of a Quality Growth strategy, emphasizing companies with durable competitive advantages, consistent earnings growth, and reasonable valuations.

Why it Makes Sense

In the current environment of moderating economic growth and elevated uncertainty, a Quality Growth approach can offer relatively defensive exposure while participating in secular growth opportunities.

High-Level Investment Process

Sourcing: The strategy appears to source investment ideas from across the market capitalization spectrum, with a focus on companies demonstrating sustainable competitive advantages and attractive growth prospects. Selection: The selection process suggests a preference for businesses with strong fundamentals, healthy balance sheets, and capable management teams, while maintaining valuation discipline. Construction: Portfolio construction is consistent with a diversified, conviction-weighted approach, with sector allocations reflecting the strategy's emphasis on quality growth opportunities.

Portfolio Holdings Overview

SectoralAllocation

Services92.46%

Capital Goods7.54%

Geographic Allocation

Domestic100%

Top Stock Holdings

CompanySectorAllocation

Sun Pharmaceuticals Industries LtdServices10.47%

J.B. Chemicals & Pharmaceuticals LtdServices6.54%

Clearing Corporation Of India LtdUtilities4.57%

Laurus Labs LtdServices4.13%

Fortis Healthcare LtdServices4.12%

Divi's Laboratories LtdServices4.11%

Apollo Hospitals Enterprise LtdServices4.02%

Glenmark Pharmaceuticals LtdServices3.41%

Aurobindo Pharma LtdServices3.33%

Max Healthcare Institute Ltd Ordinary SharesServices3.31%

Fund House Management

The asset management company’s track record, AUM scale, and fund manager credentials.

Fund Manager Track Record

Ramesh Mantri

Mr. Ramesh Mantri has experience of 23 years. Manages 52 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr Holds a M.B.A. degree.

66 years

Combined Team Experience

₹ 56,369 Cr

Assets Under Management

Dheeresh Pathak

Co-Portfolio Manager

Mr. Dheeresh Pathak has experience of 19 years. Manages 50 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr Holds a B.Com degree.

Ashish Agrawal

Co-Portfolio Manager

Ashish Agrawal has experience of 1 years. Manages 48 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr

Piyush Baranwal

Co-Portfolio Manager

Mr. Piyush Baranwal has experience of 18 years. Manages 86 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,733 Cr Holds a PGDBM degree.

Trupti Agrawal

Co-Portfolio Manager

Trupti Agrawal has experience of 4 years. Manages 50 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr

Dheeresh Pathak

Co-Portfolio Manager

Mr. Dheeresh Pathak has experience of 19 years. Manages 50 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr Holds a B.Com degree.

Ashish Agrawal

Co-Portfolio Manager

Ashish Agrawal has experience of 1 years. Manages 48 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr

Piyush Baranwal

Co-Portfolio Manager

Mr. Piyush Baranwal has experience of 18 years. Manages 86 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,733 Cr Holds a PGDBM degree.

Trupti Agrawal

Co-Portfolio Manager

Trupti Agrawal has experience of 4 years. Manages 50 funds at WhiteOak Capital Asset Management Limited with an AUM of approximately ₹11,159 Cr

CW Expert Take

WhiteOak Capital Pharma and Healthcare Fund maintains a focused portfolio of healthcare companies. Their investment philosophy centers on identifying quality businesses with sustainable growth prospects. The fund house leverages deep sector expertise, combining fundamental research with rigorous valuation discipline to construct concentrated equity portfolios.

Firm Overview

Total AUM₹29,798.08 Cr

Investment Philosophy & Approach

Focused Expertise

WhiteOak Capital employs a focused investment approach in pharma and healthcare.

Disciplined Process

The fund house follows a disciplined investment process and risk management.

Long-Term Mindset

WhiteOak Capital maintains a long-term perspective for capital allocation decisions.

Operational & Regulatory Details

What it costs to invest, transaction mechanics, and regulatory disclosures you should know.

Costs and Fees

Total Expense Ratio (TER)2.57%

Regulatory & Tax Information

INF03VN01878

ISIN

DailyDealing Frequency

BSE Healthcare PR INRBenchmark

LTCG | >1Year 12.5%% on gain above 1.25 Lakh

STCG | <1Year 20%%

Tax Implications (India)